CELU vs. LPTX, LABP, DERM, MNOV, IFRX, MRNS, SCYX, LTRN, VHAQ, and ALRN
Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Leap Therapeutics (LPTX), Landos Biopharma (LABP), Journey Medical (DERM), MediciNova (MNOV), InflaRx (IFRX), Marinus Pharmaceuticals (MRNS), SCYNEXIS (SCYX), Lantern Pharma (LTRN), Viveon Health Acquisition (VHAQ), and Aileron Therapeutics (ALRN). These companies are all part of the "pharmaceutical preparations" industry.
Leap Therapeutics (NASDAQ:LPTX) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking.
30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 11.3% of Leap Therapeutics shares are owned by insiders. Comparatively, 20.7% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Celularity has higher revenue and earnings than Leap Therapeutics.
Leap Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.
Leap Therapeutics received 282 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 68.72% of users gave Leap Therapeutics an outperform vote while only 42.11% of users gave Celularity an outperform vote.
Leap Therapeutics has a net margin of 0.00% compared to Leap Therapeutics' net margin of -1,226.72%. Leap Therapeutics' return on equity of 30.79% beat Celularity's return on equity.
Leap Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 300.00%. Given Celularity's higher probable upside, equities analysts clearly believe Leap Therapeutics is more favorable than Celularity.
In the previous week, Leap Therapeutics had 4 more articles in the media than Celularity. MarketBeat recorded 9 mentions for Leap Therapeutics and 5 mentions for Celularity. Leap Therapeutics' average media sentiment score of 0.94 beat Celularity's score of 0.77 indicating that Celularity is being referred to more favorably in the news media.
Summary
Leap Therapeutics beats Celularity on 9 of the 15 factors compared between the two stocks.
Get Celularity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celularity Competitors List
Related Companies and Tools
